Literature DB >> 11904470

Biological risk factors for deep vein trombosis.

Amparo Vayá1, Yolanda Mira, Marcial Martínez, Piedad Villa, Fernando Ferrando, Amparo Estellés, Dolores Corella, Justo Aznar.   

Abstract

Hypercoagulable states due either to inherited or acquired thrombotic risk factors are only present in approximately half of cases of DVT, but the causes in the other half, remain unknown. The importance of biological risk factors such as hyperlipidemia, hypofibrinolysis and hemorheological alterations in the pathogenesis of DVT has not been well established. In order to ascertain whether the above mentioned biological factors are associated with DVT and could constitute independent risk factors, we carried out a case-control study in 109 first DVT patients in whom inherited or acquired thrombophilic risk factors had been ruled out and 121 healthy controls age (42+/-15 years) and sex matched. From all the biological variables analyzed (cholesterol, triglycerides, glucose, fibrinogen, erythrocyte aggregation, hematocrit, plasma viscosity and PAI-1) only fibrinogen concentration reached a statistically significant difference on the comparison of means (290+/-73 mg/dl in cases vs 268+/-58 mg/dl in controls, p<0.05). After this continuous variables were dichotomized according to our reference values, the percentage of cases with cholesterolemia >220 mg/dl, hematocrit >45% and fibrinogen >300 mg/dl was higher in cases than in controls: 38% vs 22%; p<0.01; 43% vs 27%; p<0.05; 36% vs 23%; p<0.05, respectively. The percentage of cases with PAI-1 values >30 ng/ml, 37% vs 25% was borderline significant; p=0.055. Multivariate logistic regression analysis showed that cholesterolemia >220 mg/dl and fibrinogen >300 mg/dl constitute independent predictors of venous thrombotic risk. The adjusted OR's were 2.03 (95% CI; 1.12-3.70) for cholesterolemia and 1.94 (95% CI; 1.07-3.55) for fibrinogen. When these two variables combined DVT risk rose about fourfold (3.96; p<0.05). Our results suggest that hypercholesterolemia and hyperfibrinogenemia should be added to the list of known DVT risk factors and we recommend adopting measures to decrease these variables in the population with a high risk of DVT.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11904470

Source DB:  PubMed          Journal:  Clin Hemorheol Microcirc        ISSN: 1386-0291            Impact factor:   2.375


  8 in total

1.  Relationship between serum cholesterol and indices of erythrocytes and platelets in the US population.

Authors:  Michael B Fessler; Kathryn Rose; Yanmei Zhang; Renee Jaramillo; Darryl C Zeldin
Journal:  J Lipid Res       Date:  2013-09-02       Impact factor: 5.922

2.  High hematocrit as a risk factor for venous thrombosis. Cause or innocent bystander?

Authors:  Anja J M Schreijer; Pieter H Reitsma; Suzanne C Cannegieter
Journal:  Haematologica       Date:  2010-02       Impact factor: 9.941

3.  A local increase in red blood cell aggregation can trigger deep vein thrombosis: evidence based on quantitative cellular ultrasound imaging.

Authors:  F T H Yu; J K Armstrong; J Tripette; H J Meiselman; G Cloutier
Journal:  J Thromb Haemost       Date:  2011-03       Impact factor: 5.824

4.  Hematocrit and risk of venous thromboembolism in a general population. The Tromso study.

Authors:  Sigrid K Braekkan; Ellisiv B Mathiesen; Inger Njølstad; Tom Wilsgaard; John-Bjarne Hansen
Journal:  Haematologica       Date:  2009-10-14       Impact factor: 9.941

5.  No association of the plasminogen activator inhibitor-1 promoter 4G/5G polymorphism with inhibitor level during basal transcription in vitro.

Authors:  Mei Zhan; Yuling Zhou; Zhong Chao Han
Journal:  Int J Hematol       Date:  2004-05       Impact factor: 2.490

6.  Hematocrit and the risk of recurrent venous thrombosis: a prospective cohort study.

Authors:  Lisbeth Eischer; Verena Tscholl; Georg Heinze; Ludwig Traby; Paul A Kyrle; Sabine Eichinger
Journal:  PLoS One       Date:  2012-06-06       Impact factor: 3.240

7.  Age-Dependent Heterogeneity in the Efficacy of Prophylaxis With Enoxaparin Against Catheter-Associated Thrombosis in Critically Ill Children: A Post Hoc Analysis of a Bayesian Phase 2b Randomized Clinical Trial.

Authors:  E Vincent S Faustino; Leslie J Raffini; Sheila J Hanson; Jill M Cholette; Matthew G Pinto; Simon Li; Sarah B Kandil; Marianne E Nellis; Veronika Shabanova; Cicero T Silva; Joana A Tala; Tara McPartland; Philip C Spinella
Journal:  Crit Care Med       Date:  2021-04-01       Impact factor: 9.296

8.  Hematocrit and incidence of venous thromboembolism.

Authors:  Aaron R Folsom; Wendy Wang; Romil Parikh; Pamela L Lutsey; Joan D Beckman; Mary Cushman
Journal:  Res Pract Thromb Haemost       Date:  2020-03-11
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.